• Explore /
  • Poster
  • / Efficacy and safety of SY-3505, a third-generation ALK TKI, in <em>ALK</em>-positive advanced non-small cell lung cancer: Results from a phase I/II, multi-center study.

Efficacy and safety of SY-3505, a third-generation ALK TKI, in ALK-positive advanced non-small cell lung cancer: Results from a phase I/II, multi-center study.

Abstract Poster

Authors

null

Yuankai Shi

Department of Medical Oncology, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study On Anticancer Molecular Targeted Drugs, Beijing, China

Yuankai Shi , Xingsheng Hu , Xingya Li , Yongsheng Li , Ke Wang , Pingli Wang , Liyan Jiang , Shucai Zhang , Xiangjiao Meng , Huijuan Wang , Xiaorong Dong , Runxiang Yang , Yongzhong Luo , Qi Mei , Yinghui Sun

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Lung Cancer—Non-Small Cell Metastatic

Track

Lung Cancer

Sub Track

Metastatic Non–Small Cell Lung Cancer

Clinical Trial Registration Number

NCT05257512

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr 9110)

DOI

10.1200/JCO.2023.41.16_suppl.9110

Abstract #

9110

Poster Bd #

98

Abstract Disclosures

Similar Posters

First Author: Yuxiang Ma

First Author: Tony S. K. Mok

First Author: Xi Guo

First Author: Ki Hyeong Lee